ClinicalTrials.gg
Active, not recruitingNCT07228117Updated Sep 2, 2026

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

An interventional study of MiniMed™ NMX8-AID System with DS5™/Simplera Sync™ in Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus, sponsored by Medtronic MiniMed, Inc.. Active, not recruiting at 33 sites in 3 countries. Open to participants aged 7 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Medtronic MiniMed, Inc. (part of Medtronic) · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
389
Allocation
Randomized
Ages
7 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies in Diabetes Mellitus, Type 1 by Medtronic — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Medtronic.

Enrollment
4th of 54
389 · median 103
Started
2026
with 2 others
No phase
49 of 59
3 open now
Registered
57th of 59
by date

Among the 59 studies in Diabetes Mellitus, Type 1 by Medtronic, this one is the 4th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2026, is one of 49 with no phase, and was the 57th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 59 studies in Diabetes Mellitus, Type 1 by Medtronic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 7 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Diabetes Mellitus, Type 1 by Medtronic, or all of them as a file.
02

Study summary

The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Participants will use their current therapy while also wearing the DS5/Simplera sensor for up to 40 days. During this time, they will complete a meal and exercise log. Participants will then be placed into one of three groups by chance and given the NMX8 pump to use for about 90 days. During this time, participants will bolus, not bolus, or bolus at will for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if participants like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
7 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at time of screening according to diabetes type:

    1. T1D: Age 7-85 years
    2. T2D: Age 18-85 years
  2. Has a clinical diagnosis of diabetes for a minimum per diabetes type below:

    1. T1D (Age 7-85 years): Diagnosis of T1D for at least 6 months, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
    2. T2D (Age 18-85 years): Diagnosis of insulin-requiring T2D for 1 year or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  3. Is willing to provide /assent for participation.
  4. Subject or parent/caregiver is literate and able to read the language (English or Spanish) offered in the study pump or study pump materials.
  5. Is willing to wear the system continuously throughout the study.
  6. Has results of a retinal eye examination on record prior to enrollment, per guidelines by the American Diabetes Association according to age, duration of diabetes and type of diabetes:

    1. T1D adults (Age 18-85 years):

      I. Initial retinal eye exam within 5 years of diagnosis. II. If the duration of type 1 diabetes is longer than 5 years, a retinal examination should have been performed within the last 12-18 months.

    2. T2D adults (Age 18-85 years):

      I. Results of a retinal eye exam, performed within the last 12-18 months, should be on record.

    3. T1D pediatric (Age 7-17 years):

    I. No exam is required if under the age of 10 years unless the duration of diabetes is more than 3 years.

    II. For children over the age of 10, a retinal exam should have been performed within 24 months of enrollment in the study.

    Per the investigator's discretion: If a potential participant is deemed to be at high risk, a retinal eye exam, performed within the last 12 months prior to screening, should be on record.

  7. Is willing to upload study pump data via an app or computer.
  8. Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:

    1. Humalog™* (insulin lispro injection)
    2. NovoLog™* (insulin aspart solution for injection) or an interchangeable biosimilar (for example, Kirsty™*)
    3. NovoRapid™* (insulin aspart solution for injection)
    4. Admelog™* (insulin lispro injection)
    5. Merilog™* (insulin aspart)
    6. Fiasp™* (ultra-rapid-acting insulin aspart)
    7. Lyumjev™* (ultra-rapid-acting insulin lispro)
    8. Authorized generic insulin aspart
    9. Authorized generic insulin lispro

Exclusion criteria

Exclusion Criteria:

  1. Unable to consent due to a mental or intellectual disability.
  2. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following, during the 6 months prior to screening:

    1. Medical assistance (i.e., Paramedics, Emergency Room [ER] or Hospitalization)
    2. Coma or
    3. Seizures
  3. Has a history of 1 or more episodes of diabetic ketoacidosis (DKA) in the last 6 months prior to screening visit.
  4. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
  5. Has any unresolved adverse skin condition in the area of sensor or infusion set placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
  6. Currently pregnant or planning to become pregnant during the time period of study participation

    1. A negative pregnancy test will be required for all females of at time of screening
    2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of that is being used is reliable
  7. At investigator discretion, has hypothyroidism or hyperthyroidism that is not adequately treated.
  8. Has diagnosis of adrenal insufficiency.
  9. Has taken any oral, injectable, or intravenous (IV) within 8 weeks from time of screening visit.
  10. T1D: Is using non-insulin anti-hyperglycemic medication, other than metformin and/or Glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) containing medications (e.g., Mounjaro), in the 8 weeks prior to screening.

    1. Participants who have stopped using metformin and/or GLP-1/GIP have done so at least 8 weeks prior to screening.
    2. Participants currently taking metformin and/or GLP-1/GIP must be on a steady dose and remain on the same dose during study participation until the end of the study period.
    3. During continued access, starting/stopping the medication and/or modifying doses will be permitted.
    4. Dose changes and reasons for changes will be documented throughout the study.
  11. T2D: Is using non-insulin anti-hyperglycemic medication, other than metformin, GLP-1 /GIP containing medications (e.g., Mounjaro), DPP-4 Inhibitors, thiazolidinedione (TZD), or Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, in the 8 weeks prior to screening.

    1. Participants who have stopped using metformin, GLP-1/GIP, DPP-4 Inhibitors, TZD, or SGLT2 have done so at least 8 weeks prior to screening.
    2. Participants currently taking metformin, GLP-1/GIP, DPP-4 Inhibitors, TZD, or SGLT2 must be on a steady dose and remain on the same dose during study participation, until the end of the study period.
    3. During continued access, starting/stopping the medication and/or modifying doses will be permitted.
    4. Dose changes and reasons for changes will be documented throughout the study
  12. Is using sulfonylureas and meglitinides, e.g., repaglinide, in the 8 weeks prior to screening.
  13. Is using inhalable insulin in the 8 weeks prior to screening.
  14. Is using hydroxyurea at time of screening or plans to use it during the study
  15. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study.
  16. Is, at the discretion of the investigator, abusing drugs or alcohol.
  17. Is, in the opinion of the investigator, not able to perform all study procedures safely.
  18. Has a history of visual impairment which would not allow subject, even with the help of a caregiver, to participate in the study and perform all study procedures safely, as determined by the investigator.
  19. Has elective surgery planned that requires general anesthesia during the course of the study.
  20. Has sickle cell disease or other hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.
  21. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.
  22. Is diagnosed with current eating disorder such as anorexia or bulimia.
  23. Blood disorder or dyscrasia within 3 months prior to screening, which in the investigator's opinion could interfere with determination of
  24. Is on dialysis.
  25. Has an estimated (eGFR) \<30. For T1D subjects who are within the first 5 years after diagnosis, a new eGFR test is not required for screening; however, if an eGFR value taken during the first 5 years from diagnosis is available, and if it is \<30, the subject will be excluded.
  26. Has celiac disease that is not adequately treated as determined by the investigator.
  27. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, , cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
  28. Has had any of the following cardiovascular events more than 1 year prior to screening and should not participate at the discretion of the investigator: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
  29. Is a member of the research staff involved with the study.
  30. Is a Medtronic Diabetes employee or their immediate family member (excluding adult children and/or adult siblings).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
389 participants (actual)

Study arms

  • Experimental
    Arm 1 - No meal bolus administration

    Patients will be asked not to bolus for any of their meals while using the NMX8 pump.

    Device: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™

  • Experimental
    Arm 2 - Meal bolus administration at all meals

    Patients will be asked to bolus for all of their meals while using the NMX8 pump.

    Device: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™

  • Experimental
    Arm 3 - Meal bolus administration at will

    Patients are free to bolus or not bolus for their meals as they wish using NMX8 pump.

    Device: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™

Interventions

  • DeviceMiniMed™ NMX8-AID System with DS5™/Simplera Sync™

    Patients will be provided with the NMX8 system with DS5/Simplera Sync CGM.

06

What researchers measure

Primary outcomes

  1. Study Arm 1: Percent of Time in Range (TIR 70-180 mg/dL)

    Percent of time in range (TIR 70-180 mg/dL) among subjects randomized to Study Arm 1. Descriptive only.

    Time frame: Throughout the study period, approximately 90 days.

  2. Study Arm 1: Percent of Time in Hypoglycemia (< 70 mg/dL)

    Percent of time in hypoglycemia (\< 70 mg/dL) among subjects randomized to Study Arm 1. Descriptive only.

    Time frame: Throughout the study period, approximately 90 days.

  3. Study Arm 2: Percent of Time in Range (TIR 70-180 mg/dL)

    Percent of time in range (TIR 70-180 mg/dL) among subjects randomized to Study Arm 2. Descriptive only.

    Time frame: Throughout the study period, approximately 90 days.

  4. Study Arm 2: Percent of Time in Hypoglycemia (< 70 mg/dL)

    Percent of time in hypoglycemia (\< 70 mg/dL) among subjects randomized to Study Arm 2. Descriptive only.

    Time frame: Throughout the study period, approximately 90 days.

  5. Study Arm 3: Percent of Time in Range (TIR 70-180 mg/dL)

    Percent of time in range (TIR 70-180 mg/dL) among subjects randomized to Study Arm 3. Descriptive only.

    Time frame: Throughout the study period, approximately 90 days.

  6. Study Arm 3: Percent of Time in Hypoglycemia (< 70 mg/dL)

    Percent of time in hypoglycemia (\< 70 mg/dL) among subjects randomized to Study Arm 3. Descriptive only.

    Time frame: Throughout the study period, approximately 90 days.

07

Study locations

33 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 11 months is close to that.

Counting every sponsor, half of 955 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2025
First posted
Nov 14, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07228117
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Feb 2, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion